Literature DB >> 21528408

Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens.

Shusen Wang1, Yanxia Shi, Zhongyu Yuan, Xi Wang, Donggen Liu, Roujun Peng, Xiaoyu Teng, Tao Qin, Jiewen Peng, Guinan Lin, Xiaomei Jiang.   

Abstract

Patients suffering from triple-negative breast cancer (TNBC) have poor prognosis mainly because no standard treatment is currently available. Our objectives were to explore the prognostic factors for first relapse of patients with TNBC. A cohort of 687 patients with TNBC, diagnosed and treated between January 1995 and December 2008 at Sun Yat-sen University Cancer Center, were retrospectively analyzed. Cox proportional hazards models were fitted to explore factors that predict relapse development. Survival rate was computed using the Kaplan-Meier product limit method. The median age of the 687 patients was 46 (range 16-76 years), and 64.8% of the patients were pre-menopausal. The median follow-up time was 56 months (range 14-156 months), in which 194 patients had recurrence, and 115 died. The median recurrence-free time was 25 months (range 4-143 months), with 118 (60.8%) of the cases first relapsing at a single site. The three- and five-year disease-free survival rates were 79.7 and 72.6%, respectively. Primary tumor size at diagnosis, lymph node status, and type of regimen used in the (neo)adjuvant chemotherapy were considered independent predictors of first relapse. CMF-containing adjuvant chemotherapy significantly decreased recurrence compared with the anthracycline- or taxane-based regimens (RR = 0.66, 95%; CI 0.45-0.96; P = 0.030). The median time from first relapse to death was 26 months (range 2-121 months). The two- and five-year survival rates were 60.6 and 36.6%, respectively. Liver metastasis at first recurrence and progression-free survival over 12 months after first-line therapy were two important factors that affected survival rate after recurrence. The median relapse time of TNBC was about 2 years after diagnosis. CMF regimens for TNBC patients may be more effective than anthracycline- or taxane-based regimens. Liver metastasis at first recurrence signifies unfavorable prognosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21528408     DOI: 10.1007/s12032-011-9964-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  28 in total

1.  Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.

Authors:  E A Rakha; T C Putti; D M Abd El-Rehim; C Paish; A R Green; D G Powe; A H Lee; J F Robertson; I O Ellis
Journal:  J Pathol       Date:  2006-03       Impact factor: 7.996

2.  The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Authors:  Lisa A Carey; E Claire Dees; Lynda Sawyer; Lisa Gatti; Dominic T Moore; Frances Collichio; David W Ollila; Carolyn I Sartor; Mark L Graham; Charles M Perou
Journal:  Clin Cancer Res       Date:  2007-04-15       Impact factor: 12.531

Review 3.  Triple-negative breast cancer: therapeutic options.

Authors:  Susan Cleator; Wolfgang Heller; R Charles Coombes
Journal:  Lancet Oncol       Date:  2007-03       Impact factor: 41.316

4.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

5.  Subtypes of breast cancer show preferential site of relapse.

Authors:  Marcel Smid; Yixin Wang; Yi Zhang; Anieta M Sieuwerts; Jack Yu; Jan G M Klijn; John A Foekens; John W M Martens
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

6.  Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Authors:  Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

Review 7.  Triple-negative breast cancer: risk factors to potential targets.

Authors:  Bryan P Schneider; Eric P Winer; William D Foulkes; Judy Garber; Charles M Perou; Andrea Richardson; George W Sledge; Lisa A Carey
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

8.  Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases.

Authors:  Nancy U Lin; Elizabeth Claus; Jessica Sohl; Abdul R Razzak; Amal Arnaout; Eric P Winer
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

9.  Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients.

Authors:  David S P Tan; Caterina Marchió; Robin L Jones; Kay Savage; Ian E Smith; Mitch Dowsett; Jorge S Reis-Filho
Journal:  Breast Cancer Res Treat       Date:  2007-10-06       Impact factor: 4.872

10.  Breast cancer subtypes and survival in patients with brain metastases.

Authors:  Byung-Ho Nam; Sun Young Kim; Hye-Sook Han; Youngmee Kwon; Keun Seok Lee; Tae Hyun Kim; Jungsil Ro
Journal:  Breast Cancer Res       Date:  2008-02-28       Impact factor: 6.466

View more
  7 in total

1.  How do I treat "triple-negative" disease.

Authors:  Christos Vaklavas; Andres Forero-Torres
Journal:  Curr Treat Options Oncol       Date:  2011-12

2.  Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China.

Authors:  Cong Xue; Xi Wang; Roujun Peng; Yanxia Shi; Tao Qin; Donggen Liu; Xiaoyu Teng; Shusen Wang; Li Zhang; Zhongyu Yuan
Journal:  Cancer Sci       Date:  2012-07-04       Impact factor: 6.716

3.  Neuroprotective effect of Mulmina Mango against chemotherapy-induced cognitive decline in mouse model of mammary carcinoma.

Authors:  Jeena John; Manas Kinra; Niraja Ranadive; Raghuvir Keni; Pawan Ganesh Nayak; Rajesh N Jagdale; Syed M Ahmed; Kaggundi V Raghavendra; Jayesh Mudgal; K Nandakumar
Journal:  Sci Rep       Date:  2022-02-23       Impact factor: 4.379

4.  lncRNA GHET1 Promotes the Progression of Triple-Negative Breast Cancer via Regulation of miR-377-3p/GRSF1 Signaling Axis.

Authors:  Yu Wang; Chen Li
Journal:  Comput Math Methods Med       Date:  2022-04-25       Impact factor: 2.809

5.  Metabolic Response of Triple-Negative Breast Cancer to Folate Restriction.

Authors:  Michael F Coleman; Ciara H O'Flanagan; Alexander J Pfeil; Xuewen Chen; Jane B Pearce; Susan Sumner; Sergey A Krupenko; Stephen D Hursting
Journal:  Nutrients       Date:  2021-05-13       Impact factor: 5.717

6.  Somatic copy number changes in DPYD are associated with lower risk of recurrence in triple-negative breast cancers.

Authors:  E Gross; C Meul; S Raab; C Propping; S Avril; M Aubele; A Gkazepis; T Schuster; N Grebenchtchikov; M Schmitt; M Kiechle; J Meijer; R Vijzelaar; A Meindl; A B P van Kuilenburg
Journal:  Br J Cancer       Date:  2013-10-08       Impact factor: 7.640

7.  Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial.

Authors:  Safa Najafi; Mehrdad Payandeh; Masoud Sadeghi; Vahideh Shafaei; Fateme Shojaiyan; Fereshte Abbasvandi
Journal:  Contemp Oncol (Pozn)       Date:  2017-03-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.